Smith & Nephew SNATS, Inc. (NYSE:SNN) Stock Has Consensus Price Target of $31.91 According to Brokerages

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have been given a consensus rating of “Hold” by the eleven brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $31.91.

Several research firms have issued reports on SNN. Bank of America downgraded Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a report on Tuesday, September 8th. Zacks Research upgraded shares of Smith & Nephew SNATS from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 8th. Morgan Stanley downgraded shares of Smith & Nephew SNATS from an “overweight” rating to an “equal weight” rating in a research report on Wednesday, September 2nd. JPMorgan Chase & Co. restated a “neutral” rating on shares of Smith & Nephew SNATS in a report on Thursday, August 6th. Finally, Weiss Ratings lowered shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, September 24th.

Smith & Nephew SNATS Price Performance

Shares of NYSE SNN opened at $29.05 on Friday. Smith & Nephew SNATS has a 12 month low of $26.12 and a 12 month high of $37.51. The company has a quick ratio of 1.11, a current ratio of 2.14 and a debt-to-equity ratio of 0.62. The business has a fifty day simple moving average of $28.26 and a 200-day simple moving average of $30.01.

Smith & Nephew SNATS Dividend Announcement

The company also recently announced a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be paid a dividend of $0.3120 per share. This represents a yield of 236.0%. The ex-dividend date of this dividend is Friday, October 2nd.

Institutional Trading of Smith & Nephew SNATS

Hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in Smith & Nephew SNATS during the 2nd quarter worth about $505,323,000. Bank of America Corp DE purchased a new position in Smith & Nephew SNATS during the 2nd quarter valued at about $97,223,000. Bank of New York Mellon Corp acquired a new position in shares of Smith & Nephew SNATS in the 2nd quarter valued at about $89,325,000. Caisse de depot et placement du Quebec acquired a new position in shares of Smith & Nephew SNATS in the 2nd quarter valued at about $64,186,000. Finally, Legal & General Group Plc acquired a new position in shares of Smith & Nephew SNATS in the 2nd quarter valued at about $35,338,000. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company headquartered in Watford, England. Founded in 1856 by pharmacist Thomas James Smith in Hull, the company has grown from a pharmacy business into a provider of surgical and wound-care products for healthcare professionals and patients.

The company operates through three principal areas: Orthopaedics, Sports Medicine, and Advanced Wound Management. Its products include joint-replacement systems, trauma and extremity devices, arthroscopy equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products used to support healing and tissue recovery.

Smith & Nephew serves hospitals, clinics, surgeons, and patients in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific, and other international regions.